EEG
KERX

E.E. Geduld’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

E.E. Geduld’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-35,000
Closed -$163K – 196
2016
Q1 		$163K Buy
+35,000
New +$140K 0.22% 78

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

E.E. Geduld's KERX Position: Q2 2016 in Review

E.E. Geduld sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 35,000 shares — an estimated $163K sold.

E.E. Geduld first reported a position in KERX in Q1 2016 and held it in 1 quarter. The position peaked at $163K in Q1 2016. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

  • E.E. Geduld reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • E.E. Geduld sold 35,000 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $163K.
  • E.E. Geduld first reported a position in Keryx Biopharmaceuticals Inc in Q1 2016 and held it in 1 quarter.
  • E.E. Geduld's Keryx Biopharmaceuticals Inc position peaked at $163K in Q1 2016.
  • 118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on E.E. Geduld's 13F filing for Q2 2016, filed 8 Aug 2016.